NICE is pushing us to treat type 2 diabetes medicines as long-term, cardio-renal risk tools, not just “sugar tablets”. Every step should sit on top of lifestyle advice, and every drug choice should be a shared decision, balancing glycaemia, weight, CV/renal benefit, comorbidities, frailty and cost. Medicines should be reviewed and optimised before changing, with special attention to SGLT2 inhibitors, GLP-1 receptor agonists and tirzepatide for their weight and cardiovascular benefits, used safely around kidney function and frailty.

Key clinic bullets

Lifestyle foundation

• 🔁 At every medication step, reinforce: healthy diet, physical activity, weight management, smoking status, alcohol, and sleep.

• → Link weight and glycaemic targets to the separate overweight/obesity guideline; document agreed personal targets

Shared decisions about medicines

• → Explain pros/cons of each option in plain language (HbA1c effect, weight impact, side effects, long-term CV/renal protection).

• → Actively involve people in choosing their regimen; check what matters most to them (e.g. weight, injections, hypos, pill burden).

• ✔ When several drugs in the same class are equally suitable, pick the lowest cost option.

• ⚖ If multiple comorbidities (e.g. ASCVD + obesity), agree together which to prioritise when choosing meds and in what order.

What to weigh up when choosing a drug

• → Consider effect on:

  • HbA1c (strength of glucose lowering)

  • Weight (loss / neutral / gain)

  • Cardiovascular and renal outcomes

• 🚫 Check for contraindications (e.g. pioglitazone in heart failure, metformin if eGFR <30 mL/min/1.73 m²).

• 👵 In frailty, be extra careful with dose, number of meds, and hypo risk; prefer simpler, lower-risk regimens.

Sick day rules

• 📄 Build clear sick day guidance into each person’s care plan (which meds to pause when unwell, when to seek urgent help, hydration advice).

• 
  

Reviewing medicines – how to “tune” before you switch

• 🔍 Before changing therapy, optimise what they’re already on:

  • Check for adverse effects and address them.

  • Confirm they are actually taking the meds, at the right dose and formulation.

  • Revisit lifestyle advice if HbA1c is above target.

• ❓ If control is unexpectedly poor or response is atypical, consider whether this could be type 1 or another form of diabetes and check guidance on revisiting the diagnosis.

Ongoing Medicines Review – When to Continue / Stop Specific Drugs

What is NICE really emphasising here?

• Person-centred decisions, not protocol-driven prescribing. We’re expected to sit down and talk medicines through, not just “add the next drug”.

• Think beyond glucose. Every choice should consider weight, CV disease, kidney disease and frailty, not just HbA1c.

• Rational polypharmacy. Optimise what’s already prescribed and avoid unnecessary combinations (e.g. GLP-1 + DPP-4) or dangerous drugs in CKD/heart failure.

• SGLT2 and GLP-1/tirzepatide as risk-modifying drugs. NICE is clearly signalling: use and continue these for cardiovascular/renal protection and weight, not only for HbA1c.

• Safety and diagnosis check. If things don’t behave like typical T2DM, pause and think about alternative diagnoses (e.g. type 1 / LADA), especially in younger adults or those needing early insulin.

Treatment choices by comorbidity

General rules for all rows

• Start drugs one at a time, not all together.

• Only move to the next step once max tolerated dose is reached and checked.

• At any stage, if marked hyperglycaemic symptoms (polyuria, polydipsia, weight loss, fatigue):
  → Consider insulin-based treatment or a sulfonylurea, then review once glucose is back in range.

Patient Profile	Recommended Initial Treatment(s)	Notes / Alternatives
No relevant comorbidities	Modified-release (MR) metformin AND an SGLT-2 inhibitor.	If metformin is contraindicated/not tolerated, offer SGLT-2i alone.
Obesity	MR metformin AND an SGLT-2 inhibitor.	Consider adding a GLP-1 receptor agonist or tirzepatide if targets aren't met after 3 months.
CKD (eGFR >30)	MR metformin AND an SGLT-2 inhibitor.	For eGFR 20–30: Offer DPP-4i AND either dapagliflozin or empagliflozin.
CKD (eGFR <20)	Consider a DPP-4 inhibitor.	If DPP-4i is unsuitable, consider pioglitazone or insulin.
Early-onset (<40 years)	MR metformin AND an SGLT-2 inhibitor.	Consider adding a GLP-1 RA or tirzepatide early in treatment.
Heart Failure	MR metformin AND an SGLT-2 inhibitor.	SGLT-2i is recommended regardless of ejection fraction.
Established ASCVD	MR metformin AND SGLT-2 inhibitor AND SC semaglutide (up to 1mg/week).	Triple therapy is offered as the initial standard for these patients.
Frailty	MR metformin.	Only add SGLT-2i if there is no high risk of adverse events like hypotension.

Key Medication Rules and Targets table

Factor	Guidance
Metformin tolerance	If standard-release metformin is not tolerated, switch to modified-release.
SGLT-2 inhibitors	Consider continuing for cardiovascular/renal benefits even if glycaemic targets are not met.
Combination contraindication	Do not offer a GLP-1 receptor agonist (or tirzepatide) and a DPP-4 inhibitor together.
Stopping GLP-1/tirzepatide	Stop if the person becomes underweight (BMI <18.5) or if targets aren't met and there is no CV benefit.
Hyperglycaemic symptoms	If symptomatic at any stage, consider starting insulin or a sulfonylurea immediately.
Developing ASCVD	If a patient develops ASCVD after starting initial therapy, add subcutaneous semaglutide (Ozempic).

Clinic take-home for GPs

• Think “metformin + SGLT2” as standard, not metformin alone, unless frail or CKD pattern dictates otherwise.

• In ASCVD, expect triple therapy from day one: MR metformin + SGLT2i + SC semaglutide (if tolerated).

• Use comorbidity-specific pathways: different starting combos for CKD, HF, obesity, early-onset and frailty.

• Treat SGLT2i and GLP-1/tirzepatide as risk-modifying drugs (CV/renal/weight), not just sugar-lowerers.

• Never combine GLP-1 RA/tirzepatide with a DPP-4 inhibitor.

• Apply clear stop rules for GLP-1/tirzepatide (BMI <18.5, no glycaemic/CV gain).

• In frailty, simplify: fewer drugs, lowest doses, and minimise hypos and falls from SU/insulin.

• If symptomatic hyperglycaemia at any stage → consider insulin or sulfonylurea promptly, then reassess.

• 
  

• Keep reviewing: continue what helped reach agreed HbA1c/weight targets, and if the pattern doesn’t fit T2DM, revisit the diagnosis (e.g. type 1 / other forms).

In short: NG28 now expects GPs to start smarter, individualise earlier, and think heart–kidney–weight at every step, not just chase an HbA1c number.

Reference : https://www.nice.org.uk/guidance/ng28